Novo Nordisk taps Replicate Bioscience’s srRNA platform for obesity
Replicate will receive research funding and could potentially receive up to approximately US$550 million
Replicate will receive research funding and could potentially receive up to approximately US$550 million
The US generic market is crucial for Indian pharma, contributing about 35% to its total revenue, around US$ 10.7 billion
AiMeD noted that proposed GST changes—to either 5% or 18%—both present significant risks requiring carefully nuanced consideration
Anthony brings more than 25 years of pharmaceutical development and CRO experience to his expanded role
Vivo Bio Tech will have end-to-end responsibility for conducting the full spectrum of pre-clinical safety and regulatory studies
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
This acquisition expands HGM's healthcare platform capabilities in revenue cycle management
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
Projects 5X revenue growth by 2028, accelerates global market leadership and paves the way for IPO
Subscribe To Our Newsletter & Stay Updated